Clinical InvestigationAcute Ischemic Heart DiseaseTrends in characteristics of cardiovascular clinical trials 2001-2012
Section snippets
Identification of clinical trials
We reviewed all trials in cardiovascular medicine published between 2001 and 2012 in the 8 journals with the highest Web of Science impact factor in the categories “general and internal medicine” and “cardiology,” according to the 2013 edition of the Journal Citation Reports, including the New England Journal of Medicine, the Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, European Heart Journal, the Journal of the American College of Cardiology,
Publication sources and interventions studied
We identified 1,224 RCTs that cumulatively enrolled 2,350,632 participants in 98 countries (Figure 1). Of these, 267 (21.8%) were published in New England Journal of Medicine, 257 (21.0%) in Circulation, 214 (17.5%) in Journal of the American College of Cardiology), 166 (13.6%) in Lancet, 150 (12.2%) in Journal of the American Medical Association, and the remaining (13.9%) in Annals of Internal Medicine, British Medical Journal, and European Heart Journal. The most common intervention was a
Discussion
For cardiovascular clinical trials published in premier general medical and cardiology journals between 2001 and 2012, we observed that over time (1) enrollment rate decreased by ≈25%, (2) more sites were required to complete trials, and (3) trials have increased in size and geographic scope. In addition, universities or organizations funded a larger proportion of trials over time. These are important findings, considering the profound impact of RCTs on practice.
Successful conduct of RCTs
Disclosures
Dr Butler is a consultant to Amgen, Bayer, BG Medicine, Celladon, Gambro, GE Healthcare, Harvest, Medtronic, Ono Pharma, Stemedica, and Trevena. Dr Peterson reports significant research grant support from Eli Lilly & Company and Janssen Pharmaceuticals, Inc, and modest consultant/advisory board support from Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc, Pfizer, and Genentech Inc. Dr Fonarow reports significant consultant support from Novartis and Takeda, and modest
References (35)
- et al.
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial
J Am Coll Cardiol
(2013) - et al.
Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials
J Am Coll Cardiol
(2013) - et al.
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial
Contemp Clin Trials
(2012) - et al.
Rescuing clinical trials in the United States and beyond: a call for action
Am Heart J
(2013) - et al.
Recruitment for controlled clinical trials: literature summary and annotated bibliography
Control Clin Trials
(1997) - et al.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Lancet
(2010) - et al.
Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators
Am Heart J
(2015) - et al.
Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards
Am Heart J
(2007) - et al.
International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute
J Am Coll Cardiol
(2011) - et al.
Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487
J Biol Chem
(2007)
American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy?
J Am Coll Cardiol
Warfarin and aspirin in patients with heart failure and sinus rhythm
N Engl J Med
Ethical and scientific implications of the globalization of clinical research
N Engl J Med
Committee on Cancer Clinical Trials the NCI Cooperative Group Program Institute of Medicine. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program
Looking beyond translation—integrating clinical research with medical practice
N Engl J Med
Can research and care be ethically integrated?
Hast Cent Rep
Global clinical trials activity in the details. Applied clinical trials. September 1, 2007
Cited by (24)
Contemporary Trends in the Utilization of Administrative Databases in Cardiovascular Research
2019, Mayo Clinic ProceedingsImproving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory
2018, Journal of the American College of CardiologyCitation Excerpt :There appears to be a myriad of causes. Poor patient enrollment leads to slow and costly clinical trials (2). A number of factors influence patients’ decisions to participate in clinical research, including trial complexity and burden, a favorable benefit to risk profile for the experimental treatment, and the potential to help others (3).
Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review
2017, International Journal of CardiologyDefining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials
2016, Journal of Cardiac FailureCitation Excerpt :In fact, in our study, we observed a relaxation of LVEF criteria and increasing average LVEF of patients included in advanced HF trials over time. This might reflect the increasing difficulties in achieving enrollment targets in ever-larger cardiovascular clinical trials attempting to meet endpoints for diminishing efficacy margins.12,13 In turn, this creates a clear discrepancy between advanced HF definitions for clinical practice, in which a primary concern is patient identification and referral for advanced therapies, and clinical trial purposes.
Trends in Heart Failure Clinical Trials from 2001-2012
2016, Journal of Cardiac FailureCitation Excerpt :Our study demonstrated that enrollment rates were persistently low over time, at <0.7 patients site−1 month−1. These rate estimates appear to be even lower than contemporaneously conducted general cardiovascular trials and are paradoxically low considering the tremendous prevalence of HF in the general population.9 Moreover, the excess costs and resources incurred by slow trial enrollment may influence patient profiles and trial outcomes.6
Funding sources: None.